Suspension, Withdrawal and Revocation of Medical Device Registration in Kenya

Content verification date: October 30, 2026

1. Key takeaways

• Rule 11 of LN 100 of 2022 lists six categories of circumstances that can lead to withholding, suspension or revocation of registration: a request by the holder; false or misleading information in the dossier; obtaining registration by fraud; breach of the Pharmacy and Poisons Act, of these Rules, or of the conditions of the certificate; changes in formulation, composition, design specifications, quality, safety or presentation that make continued registration unsuitable; and the public interest.
• The procedural safeguard is hard: Rule 11(3) requires that, before suspension or revocation, PPB must issue a notice of intent on Form 5 and give the holder an opportunity to be heard. A suspension or revocation imposed without that procedure is procedurally defective.
• Voluntary withdrawal has its own channel: Rule 12 requires withdrawal of registration to be notified to PPB on Form 6. Withdrawal and revocation differ in legal character; the former is an act of the holder.
• Withdrawal from the market is an immediate duty: Section 2.13 of the Guidelines for Registration of Medical Devices including In-Vitro Diagnostics (HPT/PER/HTR/GUD/011) requires that once registration is suspended or revoked, the holder and all distributors must immediately cease importation and supply of the medical devices concerned, including IVDs.
• Unpaid fees also lead here: Section 2.11 of the Guidelines states that failure to pay the annual retention fee can lead to suspension and revocation. Annual retention is a continuing condition of certificate validity, not a payment formality.

2. Legal basis

3. Expert insights

Insight 1: two of the six categories are no-fault triggers in disguise

The six categories fall into two groups. The first covers situations where the holder is at fault: false information in the dossier, registration obtained by fraud, and breach of the law, the Rules or the certificate conditions. The second covers situations where the holder may be blameless yet still be sanctioned: the holder’s own request, changes in design specifications, quality, safety or presentation making continued registration unsuitable, and the public interest. GRZAN notes that the second group is the risk source companies most often overlook. When an upstream manufacturer changes design specifications or raw materials, Rule 11 can be triggered even if the holder did not know. This sets a clear compliance requirement: the holder carries a monitoring duty over upstream changes, and relying on manufacturer self-discipline is not a defence.

Insight 2: the Form 5 notice of intent is the only procedural window companies get

Rule 11(3) makes the Form 5 notice of intent and the opportunity to be heard preconditions for suspension or revocation. GRZAN considers this window severely undervalued. Receiving a Form 5 does not mean the outcome is settled; it means PPB must hear the holder before making a final decision. The quality of the company’s response at this stage often determines whether the result is revocation, suspension, or retention with conditions. The representations should be organised around three questions: whether the alleged facts stand; whether those facts fall within the Rule 11 categories; and whether the intended measure is proportionate to the risk. A submission that merely expresses willingness to improve, without addressing the legal characterisation, has limited practical effect.

Insight 3: Section 2.13 extends the duty to all distributors

The wording of Section 2.13 is that once registration is suspended or revoked, the holder and all distributors must immediately cease importation and supply of the medical devices concerned, including IVDs. The market withdrawal duty therefore does not rest on the certificate holder alone. GRZAN concludes that companies must build a distributor list and notification chain at the registration stage: the holder must be able to issue cease-supply and recall instructions to every downstream partner on the day the decision takes effect, and retain proof of delivery. If distributors keep selling, the holder may face joint liability claims. This is also the concrete landing point of the supply chain compliance duty among the ten LAR duties.

Insight 4: withdrawal on Form 6 is a proactive tool, but it leaves a pathway trace

Rule 12 requires withdrawal of registration to be notified to PPB on Form 6. GRZAN notes that in practice companies treat withdrawal as a routine exit move, yet it has follow-on effects: the withdrawal record can interact with the IBR eligibility condition of never having been rejected or withdrawn by any reference agency, the region or Kenya for quality, performance or safety reasons. A company planning to re-enter Kenya later with the same product line should assess in advance whether the withdrawal would be read as a voluntary exit or a quality-driven one, and should state the commercial reasons and a declaration of no safety grounds in the Form 6 notification.

4. Practical recommendations

1. Build an upstream change monitoring system. GRZAN recommends agreeing in the LAR contract that any change by the manufacturer to design specifications, composition, raw materials or quality standards must be notified in writing to the holder and the LAR in advance, and assessed for whether it triggers a Rule 11 category.
2. Designate a Form 5 response owner. The representation period after a notice of intent is usually short, so designate in advance who may sign written representations for the company, plus an alternate signatory.
3. Maintain the distributor list and rehearse delivery. Verify downstream distributor names and contacts annually, so that cease-supply notices can be delivered and evidenced on the day a revocation takes effect.
4. Set dual reminders for annual retention payments. The system opens for submission 60 days before the due date; set internal reminders 90 days and 70 days ahead.
5. Run a pathway impact assessment before withdrawing. If the product line may still enter Kenya in future, state the withdrawal reasons in the Form 6 notification and keep a copy.
6. Start the exemption disposal channel immediately after revocation. For export or destruction of remaining stock, submit the notification and supporting documents to PPB under Section 2.14 in advance.

5. Verification checklist

• □ Has the company mapped its current exposure against each of the six Rule 11 categories?
• □ Is a written monitoring mechanism in place for upstream changes to design specifications and quality?
• □ Are a Form 5 response owner and an alternate signatory designated?
• □ Is the distributor list up to date, and has one cease-supply delivery drill been run?
• □ Are annual retention payment reminders set for 90 days and 70 days before the due date?
• □ Has the impact of a planned withdrawal on IBR eligibility been assessed for the product line concerned?
• □ Has the Section 2.14 exemption notification for disposal of stock after revocation or suspension been submitted in advance?

Regulatory information verified as of October 30, 2026.

In African markets, the GRZAN regulatory team focuses on Kenya, Nigeria, South Africa and Egypt and verifies every published regulatory conclusion against official gazettes, competent authority guidelines and public legal databases, with the verification date marked; figures, cycles and amounts not locatable in official sources are marked as practical estimates, not presumed.

GRZAN services cover market access strategy and risk classification; preparation and review of dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); QMS and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import clearance and PVoC coordination; regulatory intelligence subscriptions and compliance ledgers.

For guidance on suspension, withdrawal, revocation and Form 5 responses in Kenya, please contact the GRZAN regulatory team at info@grzanglobal.com.